Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Scinai Immunotherapeutics Ltd.SCNI · Entity 8547 | Director · Chief Executive Officer | June 16, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Scinai Immunotherapeutics Ltd.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 711,637,600 |
Reported balance
After 2026-06-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 400,000,000 · Balance 711,637,600 F1: The Ordinary Shares are no par value per share, and are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares. F2: Includes 400,000,000 Ordinary Shares represented by restricted share units ("RSUs") granted on June 16, 2026, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. F3: Includes 71,637,600 Ordinary Shares represented by RSUs granted on January 25, 2024, of which 25% vested on the six-month anniversary thereof, 8.33% vested on the one-year anniversary thereof, and 66.66% vest in two equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. Each RSU represents a contingent right to receive one Ordinary Share upon vesting. F4: Includes 240,000,000 Ordinary Shares represented by RSUs granted on December 22, 2025, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares are no par value per share, and are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares.
F2: Includes 400,000,000 Ordinary Shares represented by restricted share units ("RSUs") granted on June 16, 2026, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates.
F3: Includes 71,637,600 Ordinary Shares represented by RSUs granted on January 25, 2024, of which 25% vested on the six-month anniversary thereof, 8.33% vested on the one-year anniversary thereof, and 66.66% vest in two equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. Each RSU represents a contingent right to receive one Ordinary Share upon vesting.
F4: Includes 240,000,000 Ordinary Shares represented by RSUs granted on December 22, 2025, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 18:48 UTC | Scinai Immunotherapeutics Ltd. SCNI · Entity 8547 | GrantOrdinary Shares | 400,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-003259 · zk2635577.xml · nonDerivative · entry 1 Reichman Amir · CIK 0001960199 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 711,637,600 F1 · security: The Ordinary Shares are no par value per share, and are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares. F2 · shares: Includes 400,000,000 Ordinary Shares represented by restricted share units ("RSUs") granted on June 16, 2026, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. F3 · balance_after: Includes 71,637,600 Ordinary Shares represented by RSUs granted on January 25, 2024, of which 25% vested on the six-month anniversary thereof, 8.33% vested on the one-year anniversary thereof, and 66.66% vest in two equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. Each RSU represents a contingent right to receive one Ordinary Share upon vesting. F4 · balance_after: Includes 240,000,000 Ordinary Shares represented by RSUs granted on December 22, 2025, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.